Compare
Vor Biopharma Inc. vs REGENXBIO Inc. vs Vericel Corp vs ImmunityBio, Inc.
| Latest fiscal year | Vor Biopharma Inc. VOR | REGENXBIO Inc. RGNX | Vericel Corp VCEL | ImmunityBio, Inc. IBRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $170.44M | $276.26M | $113.29M |
| Revenue growth (YoY) | n/a | +104.5% | +16.5% | +668.3% |
| Gross margin | n/a | n/a | 74.4% (computed) | n/a |
| Operating margin | n/a | -94.6% | 4.0% | -226.0% |
| Net margin | n/a | -113.8% | 6.0% | -310.2% |
| Net income | -$695.98M | -$193.88M | $16.52M | -$351.40M |
| EPS (Diluted) | -$70.50 | -$3.76 | $0.32 | -$0.38 |
| Operating cash flow | -$142.71M | -$123.96M | $51.91M | -$304.94M |
| Free cash flow | -$143.65M | -$126.38M | $24.75M | -$308.78M |
| Cash & equivalents | $396.49M | $34.47M | $100.09M | $88.33M |
| Total assets | $464.13M | $453.03M | $487.97M | $501.90M |
| Total liabilities | $628.44M | $350.30M | $133.33M | $1.00B |
| Shareholders' equity | -$164.31M | $102.73M | $354.64M | -$500.47M |
| Return on year-end equity | n/a | -188.7% | 4.7% | n/a |
| Shares outstanding | 38.72M | 50.89M | 50.62M | 1.01B |
Revenue, most recent five fiscal years
| Fiscal year | Vor Biopharma Inc. | REGENXBIO Inc. | Vericel Corp | ImmunityBio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $170.44M Ended 2025-12-31 | $276.26M Ended 2025-12-31 | $113.29M Ended 2025-12-31 |
| 1 year earlier | n/a | $83.33M Ended 2024-12-31 | $237.22M Ended 2024-12-31 | $14.74M Ended 2024-12-31 |
| 2 years earlier | n/a | $90.24M Ended 2023-12-31 | $197.52M Ended 2023-12-31 | $622.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $112.72M Ended 2022-12-31 | $163.70M Ended 2022-12-31 | $240.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $470.35M Ended 2021-12-31 | $153.07M Ended 2021-12-31 | $934.0K Ended 2021-12-31 |